Wilson’s Disease Treatment Market By Treatment, Distribution Channel Industry Forecast till 2025

Image Credit : primehealthchannel

Wilson’s disease is a genetic disorder caused by the loss of function of the ATP7B copper-binding protein that leads to impaired copper transport and excretion, which results in accumulation of free copper in the bloodstream that results in damage of liver, brain, and other organs. As Wilson’s disease is hard to differentiate from other serious hepatic or neurologic condition that result in less number of patient to be diagnosed than the actual prevalence of Wilson’s disease. Wilson’s disease is characterized by the degree of accumulation of free copper in liver and the brain. Whereas, the patients that suffer from Wilson’s disease can either be asymptomatic or can have one or more clinical symptoms which can vary in type and its severity that include liver disease, neurologic manifestations and psychiatric disturbances. The symptoms for Wilson’s disease may include abdominal pain, lack of appetite, fatigue, jaundice, problems with speech, swallowing or physical coordination and uncontrolled movements or muscle stiffness.

Wilson disease is suspected in the individual of age 3 – 60 years, whereas the chance of child inheriting autosomal recessive mutation from both the parent by gene mutation is 25% or one in four ratio.

Get The Holistic SAMPLE With Research Methodology:


The global Wilson’s disease treatment market was valued at US$ 392.0 million in 2016 and is expected to witness a robust CAGR of 6.0% during the forecast period (2017-2025).

Wilson’s Disease Treatment Market Value (US$ Million), 2017

wilsons disease market

Source: Coherent Market Insights 2017

Rapid advancements in technology allowing for early detection driving growth of the Wilson’s disease treatment market

North America accounts for the largest share in the global Wilson’s disease treatment market, followed by Europe. This is mainly attributed due to rapid growth in aging population in these regions. Asia Pacific is expected to emerge as a fast growing market for Wilson’s disease over the forecast period. Increasing population in China and India position these as highly lucrative markets for Wilson’s disease treatment. Increase in health expenditure on healthcare further fuels growth of Wilson’s disease treatment market in the region. The market is expected to show high growth rate in Asia Pacific region over the forecast period as Asia consist of 60% of the world’s current population and as Wilson’s disease is a hereditary disease the chance of expansion of this disease is more in Asia Pacific region. According to National Institute on Aging in 2010 it was estimated that 524 million people were aged 65 or older that is 8% of the world’s population and by 2050, which is expected to nearly triple the number to 1.5 billion, representing 16% of the world’s population. This above mentioned statistics is expected favor the growth of Wilson’s disease treatment market.

Increase in awareness regarding Wilson’s disease is expected to fuel the Wilson’s disease treatment market in near future

There are various organization and association working to create the awareness regarding Wilson’s disease for example, Wilson’s disease association is a volunteer organization striving to promote the well-being of the patients with Wilson’s disease where they offer the latest information about disease and its symptoms and treatment. Moreover Wilson’s disease association supports research and clinical investigation for Wilson’s disease.

Furthermore, manufacturers also significantly supports the Wilson’s disease awareness programs for example, in 2016, Valeant pharmaceutical announced company’s commitment to improve the lives of Wilson’s disease patients around the world, whereas Valeant has agreed to provide US$ 100,000 to fund enhanced patient awareness and research into the Wilson’s disease.

Some major players operating in the Wilson’s disease treatment market are Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc. and Tsumura & Co.

Few growth restraining factors are due to diagnosing and less awareness regarding the symptoms of the Wilson’s disease among the people hampers growth of the Wilson’s disease treatment market.

Ask For Customisation:


You may be interested

Plastisols Market Applications, Types and Market Analysis to 2026
Chemicals and Polymer Science
Chemicals and Polymer Science

Plastisols Market Applications, Types and Market Analysis to 2026

Alex Mathew - August 14, 2018

Plastisols Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share, segmentation,…


Phytonutrients Market Revenue Growth Predicted by 2025

Mohit Joshi - August 14, 2018

Phytonutrients Market report provides the statistical analysis of “Phytonutrients Market: Global Industry Analysis, Size, Share, Growth, Trends, Outlook and Forecasts” present in the industry space. The report helps…

Chemicals and Polymer Science

Citric Acid Market Headed for Growth and Global Expansion by 2026

Mohit Joshi - August 14, 2018

Citric Acid Market report provides the statistical analysis of “Citric Acid Market: Global Industry Analysis, Size, Share, Growth, Trends, Outlook and Forecasts” present in the industry space. The…

Most from this category